Analysis: For tech investors, it's hard to know when to bolt

When Hewlett-Packard Co agreed to buy British software company Autonomy in August last year for $11.1 billion, two well-known investors made diametrically different bets on how the big deal would play out.
To short seller Jim Chanos, who had been raising red flags on Autonomy for years and had started shorting shares of HP in 2011, the deal was another nail in the coffin of the Silicon Valley tech giant, according to a source familiar with his thinking.
But to activist investor Ralph Whitworth, co-founder of Relational Investors LLC, it was time to commit to HP and the turnaround story the company was trying to sell to Wall Street. His fund bought more than 17.5 million HP shares after the deal was announced, and Whitworth received a seat on the company's board. This year, Relational roughly doubled its stake in HP.
In the wake of HP's decision to take an $8.8 billion write-down on the deal because of alleged accounting irregularities at Autonomy, it appears Chanos - whose call to short Enron before the energy company collapsed in a corporate scandal may be his most famous trade - was more astute.
HP's shares are down 36 percent since Relational, which declined to comment, built its stake in the third quarter of 2011.
BARRIERS TO ENTRY
Relational's big move into HP is a reminder that even smart investors can get things wrong in the fast-evolving technology sector, where once hot global names like Research in Motion and Yahoo can quickly become yesterday's news.
It is a world where a company may effectively erect barriers to entry in a market only to have them torn down by a rival with a new whizz-bang product - just as Apple's iPhone broke the dominance that Research in Motion's BlackBerry had enjoyed.
One warning sign that a tech company may be on the verge of losing its edge is when it makes acquisitions outside of its main area of expertise to move into new product lines. Savvy tech investors also say be wary of companies that experience a succession of management changes, or when a successful core business starts looking tired.
The pace of change in the technology sector is much faster than in other industries, said Kaushik Roy, an analyst at Hercules Technology Growth Capital. "It attracts new talent and capital, many startups are formed, which can be extremely disruptive to incumbents," Roy said. "In other words, yesterday's winners can rapidly become today's losers and vice versa."
In the case of HP, the company not only has had four CEOs since 1999, it has been striving to find another niche to dominate as demand for one of its core products - computer printers - wanes and as its PC business stumbles.
Or consider online search pioneer Yahoo, which has gone through six chief executives and is struggling to keep pace with Google.
Josh Spencer, a portfolio manager at T. Rowe Price, said frequent turnover in the executive suite at Yahoo was a warning sign to him. Spencer said he does not own Yahoo shares and has not in the recent past.
RED FLAGS
While a company may view an acquisition as a fresh start - that is what HP was trying to say about Autonomy - some investors see it as a warning the core business is struggling.
Spencer noted that the technology industry's most successful companies - Apple and Samsung - generally have not made acquisitions and instead developed new products internally.
For Margaret Patel, managing director at Wells Capital Management, one of the first red flags she saw at HP was when former CEO Carly Fiorina bought Compaq for roughly $25 billion in 2002.
"I felt then that the acquisition was too large and expensive, and personal computers were not their core strength," said Patel, who has since avoided investing in HP.
Of course, timing can be everything even if an investor is eventually proven right. Patel missed out on a 137 percent gain in HP's stock price from the time of the Compaq deal up until the end of 2010.
PREMIUM VALUATIONS
A few money managers see a flashing yellow light in the big sell-off of Apple shares in the past few months.
Apple, the most valuable U.S. company, has shed nearly 30 percent of its value in the last three months.
Since the death of co-founder Steve Jobs - the driving force behind Apple's iPod, iPhone and iPad - DoubleLine co-founder Jeffrey Gundlach has been recommending that investors short the company's shares because "the product innovator isn't there anymore."
Gundlach said he began shorting Apple's stock at around $610 and maintains that it could drop to $425. He declined to comment on Tim Cook, who succeeded Jobs over a year ago and is seen by many as less visionary and innovative than Jobs.
Christian Bertelsen, chief investment officer at Global Financial Private Capital, with assets under management of $1.7 billion, said his firm began paring back its exposure to Apple this fall because he felt the expectations for the company's new iPhone5 had gotten overheated.
He said his firm dramatically took down its exposure to Apple shares when the stock hit $670 a share. "For us, the light bulb went off this fall," he said. Mind you, Apple's shares still remain up about 25 percent for the whole year.
And then there's Research in Motion. Once a leader in smartphones, it's now in danger of becoming irrelevant.
"They saw the move towards all touch-screen phones and didn't move with it," said Stuart Jeffrey, an analyst at Nomura Securities who noted how the BlackBerry 10 touch-screen phone will debut on January 30, 2013, six years after Apple released its first iPhone in 2007.
Robert Stimpson, a portfolio manager at Oak Associates Funds whose fund does not own any shares of Research in Motion, said the company's BlackBerry phones are on a downward slope and it will be tough for the company to regain its lost luster.
"The end of the road is a long, lonely journey," Stimpson said of Research in Motion. "I think they will fight the good fight for many years, probably unsuccessfully.
Read More..

The Trouble with Adam Lanza's DNA

In a rare and now controversial investigation, scientists have been asked by Connecticut's medical examiner to study Sandy Hook shooter Adam Lanza's DNA — but the DNA community doesn't think that's such a good idea. Though details on the research are scant, University of Connecticut geneticists will apparently be looking for biological clues that might explain Lanza's extreme violent behavior. The New York Times's Gina Kolata reports that this undertaking is thought to be the first time scientists have studied the genome of a mass killer. Baylor College of Medicine's genetics professor Arthur Beaudet endorses the research, saying, "By studying genetic abnormalities we can learn more about conditions better and who is at risk."
RELATED: Nancy Lanza Reportedly Wasn't a Teacher at Sandy Hook Elementary
But the ethical implications of singling out genetic mutations to explain violent behavior trouble many other scientists, who worry that such research might be held against innocent people who happen to share some of Lanza's genetic features. Harvard Medical School's Dr. Harold Bursztajn told ABC News that he's not sure what the U. Conn geneticists will "even be looking for at this point," considering how thorny and full of false positives the link between genetic markers and violence is. So far, the strongest evidence that genetics play a role in violent behavior comes out of research on MAOA, a gene that produces a substance called monoamine oxidase. Studies from the early '90s showed that abused children with certain variations of this gene had problems regulating their aggressive impulses. But University of Pennsylvania criminologist Adrian Raine questions how crucial MAOA is in determining who actually becomes violent. University of California San Francisco geneticist Robert Nussbaum also worries about the potential for genetic discrimination:
It’s a shot in the dark that’s unlikely to show anything. If they find something associated with autism, I’m afraid that it might have the effect of stigmatizing autistic people. I can see a whole morass coming out of this.
Here are some of the many other geneticists who don't think meaningful conclusions can be drawn from such studies, fearing what the general public would make out of such information:
No conclusions can be drawn from n=1, a prioriMT @mims: Geneticists to study the DNA of Adam Lanza nytimes.com/2012/12/25/sci…#protectresearch
— Ashley Ng (@drng) December 25, 2012
@dgmacarthur @edyong209 This is essentially celebrity genomics. Scientifically useless but amusing in some cases. Not amusing in this one.
— Joe Pickrell (@joe_pickrell) December 26, 2012
@joe_pickrell @dgmacarthur @edyong209 I agree, but while nobody cares about Ozzy's genome, what will people with this one? Test their kids?
— Nicolas Robine (@notSoJunkDNA) December 26, 2012
Many journalists who cover genetic research for a living also remain skeptical:
Groan. Sequencing Adam Lanza's DNA will tell us what? Will prevent what? Seriously? nyti.ms/Tob8GD
— Amy Maxmen (@amymaxmen) December 26, 2012
Crazy-misguided: Geneticists are going to study the DNA of Adam Lanza to look for clues about what was wrong with him. nytimes.com/2012/12/25/sci…
— Christopher Mims (@mims) December 25, 2012
Genomic analysis of Adam Lanza planned - the type of project that makes you question someone's grasp of genetics nytimes.com/2012/12/25/sci…
— Ed Yong(@edyong209) December 25, 2012
Read More..

Apple online customer satisfaction drops to lowest point in four years

In a survey of more than 24,000 customers, Apple’s (AAPL) online customer satisfaction during the Thanksgiving and Christmas shopping seasons was found to be at its lowest in the past four years according to Forsee, an industry analyst firm. Apple slipped out of the top five for highest online customer satisfaction during the holiday shopping season, falling to a score of 80/100 – a drop of three points from 2011. Meanwhile, Amazon (AMZN) maintained its spot at the top with a score of 88/100. Forsee’s survey based the scores on “appeal of merchandise, website functionality, and the quality of website content.” The survey’s full findings are available below.
Read More..

Record-breaking 17.4 million Android and iOS devices activated on Christmas Day; tablets top smartphones

More Android and iOS devices were activated on Christmas Day this year than on any other day. According to analytics firm Flurry, 17.4 million Android and iOS devices were activated during the holiday, an increase of 332% compared to an average of 4 million activations per day. This year’s numbers were found to be more than two and a half times larger than Christmas Day last year, which saw 6.8 million devices activated. Once their smartphones and tablets were turned on, consumers collectively downloaded 328 million applications.
[More from BGR: Google names 12 best Android apps of 2012]
[More from BGR: Samsung looks to address its biggest weakness in 2013]
Interestingly, Flurry found that for the first time ever, more tablets (51% of all activations) were activated on Christmas than smartphones (49% of all activations). The big winners were said to be Apple’s (AAPL) iPad and iPad mini, and Amazon’s (AMZN) 7-inch Kindle Fire HD tablet.
The firm notes that “Amazon had a very strong performance in the tablet category, growing by several thousand percent over its baseline of tablet activations over the earlier part of December.
Read More..

iOS apps see Christmas sales spike shrink in 2012

Distimo just released its statistics on Christmas Day app downloads and revenue growth… and the download spike is far smaller than it was last year. Back in 2011, Christmas Day iOS app download volume spiked 230% above the December average. This year, the increase was just 87% — far below industry expectations. The revenue spike came in at 70%.
[More from BGR: Google names 12 best Android apps of 2012]
Interestingly, iPad downloads increased by 140% this Christmas, implying that the iPhone download bounce was really modest.
[More from BGR: New purported BlackBerry Z10 specs emerge: 1.5GHz processor, 2GB RAM, 8MP camera]
A few weeks ago, AppAnnie released statistics showing that iOS app revenue growth had stalled over the summer of 2012, whereas Android app revenue growth was relatively strong at 48% over a five month period. Both Distimo and Appannie are respected companies and their analytics are closely followed by app industry professionals. Could it be that the pace of iPhone app revenue growth has slowed down sharply from 2011 levels, even if Distimo and AppAnnie numbers aren’t entirely accurate?
Read More..

Drugs group Lundbeck's shares hit by profit warning

 Shares in Danish drugs firm Lundbeck fell to their lowest level in over 12 years on Wednesday after it cut its profits forecast for the next two years as European sales slow and spending on new products rise to combat generic competition.
The company has already warned that earnings would stall until 2015 due to cheap generic competition for its existing drugs, meaning new products will be vital for future earnings.
But Chief Executive Ulf Wiinberg said on Wednesday that the negative impact on revenue from healthcare reforms in Europe had also been bigger than expected in the last two years and that slowing European sales and generic competition were hurting.
As a result the company said operating profits would fall further than previously forecast in 2014 as it increases investments in its late-stage drugs development pipeline and product launches.
Lundbeck is working to find new drugs to replace lost revenue from products coming off patent protection such as its antidepressant Cipralex, which is sold as Lexapro in the United States and Japan, and Alzheimer's drug Ebixa.
Wiinberg said 2014 would be the company's peak investment year for the new products pipeline, offering it a solid foundation for growth starting in 2015.
"You only get one chance to launch a product and we have to do it well," Wiinberg said at a briefing for investors.
He was commenting after the company warned in a statement that it now expects revenue in 2014 of about 14 billion Danish crowns ($2.5 billion) and an operating profit of between just 0.5 billion and 1 billion crowns.
Analysts have on average been forecasting a profit of over 2.5 billion crowns for 2014 on turnover of over 14.7 billion crowns, according to Thomson Reuters I/B/E/S Estimates.
Two years ago Lundbeck predicted its annual revenues over the period 2012-2014 would exceed 14 billion crowns a year while earnings before interest and tax (EBIT) would exceed 2 billion crowns a year.
Next years' revenue is now forecast to be in the range of 14.1 billion and 14.7 billion crowns to produce an operating profit of 1.6 billion to 2.1 billion crowns, with no change to the company's forecast for 2012.
Analysts' forecasts for this year are for operating profit to drop 41 percent to 1.99 billion crowns on revenue down 8 percent at 14.7 billion crowns, while for 2013 they predict a profit of 2.26 billion crowns on revenue of 14.5 billion crowns.
Lundbeck's shares were trading down 17 percent at 79.90 crowns at 12.44 p.m. British time, dropping below 80 crowns for the first time since April 2000.
"In the short term, earnings are under pressure," Sydbank analyst Soren Hansen said.
Lundbeck said that it expects a dividend payout ratio of about 35 percent of net profits in the 2012-14 period. Last year it paid 3.49 crowns on basic earnings per share of 11.64 crowns, a payout ratio of 30 percent.
Analysts have been predicting a 27-30 percent cut this year to 2.53-2.28 crowns, according to Thomson Reuters StarMine data.
But a number of analysts doubt that revenue from new products will be enough to secure revenue growth in 2015, compensating for lost revenue from Cipralex, Lexapro and Ebixa which together accounted for about 70 percent of group revenue in 2011.
Lundbeck is working on new products such as antidepressant Brintellix in Europe and the United States for launch at the end of next year or start of 2014, as well as alcohol dependency treatment Selincro in Europe in mid 2013.
"It is difficult to see revenue from the smaller products compensating for the large products," said Hansen.
Read More..

New Mauritius Hotels posts 25 pct drop in full-year profit

Luxury hotels group New Mauritius Hotels (NMH) reported a 25 percent fall in full-year pretax profit, citing higher finance costs and fewer tourists, and forecast a 15 percent drop in first-quarter earnings.
Ranked among the Indian Ocean island's most-traded stocks, NMH said on Wednesday that pretax profit for the year to September 30 fell to 603 million Indian rupees, with earnings per share down 20 percent at 3.60 rupees.
The hotels group said that it won't pay a dividend this year, given the difficult conditions in the local tourism industry. Last year it paid a dividend of 2.50 rupees per share.
Shares in the group, which owns eight hotels in Mauritius and one in the Seychelles, closed unchanged at 52 rupees before its results were released.
Tourism, a traditional cornerstone of the Mauritius economy, has been forecast to account for 7.9 percent of domestic product in 2012, down from 8.4 percent last year. The downturn in tourism has been caused largely by economic turmoil in the euro zone - the sector's key source market.
Read More..